MedTrace Logo

Efficacy of Aerosal® in the Treatment of Inverse Psoriasis and Sebopsoriasis

NCT01574872 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2014-11-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of Aerosal® compared to placebo in the prognosis of inverse psoriasis or sebopsoriasis present for at least one year

Conditions

  • Inverse Psoriasis
  • Sebopsoriasis

Interventions

DEVICE

Halotherapy

The treatment consist of 15 session of micronized iodized salt (sodium chloride) skin exposure in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.

DEVICE

Placebo

The treatment consist of 15 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.

Sponsors & Collaborators

  • Centro Studi Gised

    collaborator OTHER

  • Tecno Sun SRL

    lead INDUSTRY

Principal Investigators

  • Luigi Naldi, MD · Centro Studi Gised

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2013-01-31
Completion
2013-04-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01574872 on ClinicalTrials.gov